<DOC>
	<DOCNO>NCT00378378</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy Nasonex® ( Mometasone Furoate Nasal Spray ( MFNS ) ) treatment nasal polyp pediatric subject age 6 less 18 year old . Safety primary focus study .</brief_summary>
	<brief_title>Study Nasonex® Treatment Nasal Polyps Pediatric Subjects Between Ages 6 Less Than 18 Years Old ( P04292 )</brief_title>
	<detailed_description />
	<mesh_term>Polyps</mesh_term>
	<mesh_term>Nasal Polyps</mesh_term>
	<mesh_term>Mometasone Furoate</mesh_term>
	<criteria>A subject must 6 &lt; 18 year age , either sex , race . A subject must diagnosis bilateral nasal polyp . A subject must minimum nasal congestion/obstruction An asthmatic subject may include . A subject 's clinical laboratory test ( hematology , blood chemistry , urinalysis ) must within normal limit clinically acceptable investigator/sponsor . The subject parent/guardian must willing give write informed consent , subject must able adhere dose visit schedule . A female subject childbearing potential sexually active must use medically accept method contraception prior Screening must continue use receive protocolspecified medication . If premenarche female subject begin menstruate study , serum pregnancy test must do next visit A subject antrochoanal polyp . A subject cystic fibrosis . A subject acute sinusitis , concurrent upper respiratory tract infection , upper respiratory tract infection within 2 week prior Screening Visit . A subject clinically significant condition situation , condition study , opinion investigator , would interfere study evaluation optimal participation study . A subject immunocompromised . A subject ongoing rhinitis medicamentosa . A subject Churg Strauss syndrome . A subject dyskinetic ciliary syndrome , eg , Young 's syndrome ( sinopulmonary infection obstructive azoospermia ) Kartagener 's syndrome ( immotile cilium ) . A subject clinically significant pretreatment laboratory , vital sign , ECG abnormality . A subject allergy/sensitivity aspirin , corticosteroid , study drug excipients . A subject observed medication washout time outline protocol prior Screening Visit . A female subject breastfeeding , pregnant , intend become pregnant . A subject use investigational drug within 30 day Screening . A subject part staff personnel directly involve study .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>